Fred Gebhart

Bimatoprost insert offers noninvasive platform for early glaucoma patients A 19-month, open-label study of a novel bimatoprost, sustained-release ocular insert shows good safety and efficacy. The insert is polymer ring that sits atop the eye in the conjunctival fornix. Phase III trials are expected to begin in 2017.
Why single-instrument screening for keratoconus remains a dreamThe promise of simple, objective, single instrument-based screening for highly asymmetric keratoconus in patients considering LASIK is still more of an idea than reality. Multiple metrics can identify early keratoconus in a minority of affected eyes, but none of the metrics consistently identify early corneal abnormalities and none of the metrics identify the same eyes as being at elevated risk for ectatic disease.
New corneal inlay offers choice for presbyopia improvementAn implantable corneal inlay recently approved by the FDA gives ophthalmologists a new choice in treating presbyopia.
Creating corneal inlay pockets with femtosecond laser technologyA surgeon with clinical experience with three femtosecond lasers discusses the practicalities of creating ideal femtosecond laser inlay pockets.
New drape speeds ophthalmic surgery
New drape speeds ophthalmic surgerySurgical draping for ophthalmic surgery has never been quick or easy—until now. A new drape design allows the surgeon or scrub nurse to fully drape the patient in seconds.
Three companies on the “Horizon” with glaucoma drugsThe pace of new glaucoma drug development continues, fueled by continuing research into novel mechanisms of action. Three companies, Aerie Pharmaceuticals, Bausch + Lomb, and Inotek Pharmaceuticals, shared their latest results.
B + L dedicated to eye care with strong portfolio, new programsBausch + Lomb (B + L) outlines the company's commitment to eye care with a strong portfolio, new programs, patient access, and better pricing.
FDA making changes in approval processes for industry, patientsThe laws governing ophthalmic drug and device approvals have changed little in recent years. But the FDA is making significant and far-reaching changes in its approvals process.
Allergan building presence in glaucoma with implant and MIGS deviceAllergan is moving forward with plans to introduce innovative drug delivery device and surgical device for glaucoma
Device makers swing for fence with new technologiesDevice manufacturers presenting new implants and technologies to treat glaucoma. As the industry moves from 1.0 devices to 2.0 devices, this will be a transformative time in the way physicians treat patients.